Division of Nephrology and Hypertension, Mayo Clinic , Rochester, Minnesota.
Division of Hematology, Oncology and Transplantation, University of Minnesota , Minneapolis, Minnesota.
Am J Physiol Renal Physiol. 2018 May 1;314(5):F906-F914. doi: 10.1152/ajprenal.00432.2017. Epub 2017 Oct 4.
Destabilized heme proteins release heme, and free heme is toxic. Heme is now recognized as an agonist for the Toll-like receptor-4 (TLR4) receptor. This study examined whether the TLR4 receptor mediates the nephrotoxicity of heme, specifically, the effects of heme on renal blood flow and inflammatory responses. We blocked TLR4 signaling by the specific antagonist TAK-242. Intravenous administration of heme to mice promptly reduced renal blood flow, an effect attenuated by TAK-242. In vitro, TAK-242 reduced heme-elicited activation of NF-κB and its downstream gene monocyte chemoattractant protein-1(MCP-1); in contrast, TAK-242 failed to reduce heme-induced activation of the anti-inflammatory transcription factor Nrf2 and its downstream gene heme oxygenase-1 (HO-1). TAK-242 did not reduce heme-induced renal MCP-1 upregulation in vivo. TAK-242 did not reduce dysfunction and histological injury in the glycerol model of heme protein-induced acute kidney injury (AKI), findings corroborated by studies in TLR4 and TLR4 mice. We conclude that 1) acute heme-mediated renal vasoconstriction occurs through TLR4 signaling; 2) proinflammatory effects of heme in renal epithelial cells involve TLR4 signaling, whereas the anti-inflammatory effects of heme do not; 3) TLR4 signaling does not mediate the proinflammatory effects of heme in the kidney; and 4) major mechanisms underlying glycerol-induced, heme protein-mediated AKI do not involve TLR4 signaling. These findings in the glycerol model are in stark contrast with findings in virtually all other AKI models studied to date and emphasize the importance of TLR4-independent pathways of heme protein-mediated injury in this model. Finally, these studies urge caution when using observations derived in vitro to predict what occurs in vivo.
不稳定的血红素蛋白释放血红素,游离血红素是有毒的。血红素现在被认为是 Toll 样受体 4 (TLR4) 受体的激动剂。本研究探讨了 TLR4 受体是否介导血红素的肾毒性,特别是血红素对肾血流量和炎症反应的影响。我们通过特异性拮抗剂 TAK-242 阻断 TLR4 信号。血红素静脉注射到小鼠体内可迅速降低肾血流量,TAK-242 可减轻这种作用。在体外,TAK-242 降低了血红素诱导的 NF-κB 及其下游基因单核细胞趋化蛋白-1(MCP-1)的激活;相反,TAK-242 未能降低血红素诱导的抗炎转录因子 Nrf2 及其下游基因血红素加氧酶-1(HO-1)的激活。TAK-242 不能降低血红素诱导的体内肾 MCP-1 上调。TAK-242 不能减少甘油诱导的血红素蛋白急性肾损伤(AKI)模型中 TLR4 和 TLR4 小鼠的肾功能障碍和组织学损伤。我们得出结论:1)急性血红素介导的肾血管收缩通过 TLR4 信号发生;2)血红素在肾上皮细胞中的促炎作用涉及 TLR4 信号,而血红素的抗炎作用则不涉及;3)TLR4 信号不介导血红素在肾脏中的促炎作用;4)甘油诱导的、血红素蛋白介导的 AKI 的主要机制不涉及 TLR4 信号。这些在甘油模型中的发现与迄今为止研究的几乎所有其他 AKI 模型中的发现形成鲜明对比,强调了 TLR4 独立途径在该模型中血红素蛋白介导损伤的重要性。最后,这些研究告诫人们在使用体外观察结果来预测体内发生的情况时要谨慎。